-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Psoriatic arthritis (PsA) is an inflammatory disease in which the patient's immune system produces inflammation, which can lead to skin damage, painful swelling, and stiffness in the joints
.
PsA is a chronic inflammatory joint disease associated with psoriasis, which is a seronegative inflammatory arthritis with several clinical features that distinguish it from rheumatoid arthritis
(RA) .
Immune Rheumatoid Arthritis The UK National Institute for Health and Care Excellence (NICE) has issued a Final Assessment Decision (FAD) recommending Rinvoq (upadacitinib) as a new option for the treatment of adults with active psoriatic arthritis (PsA)
Upadacitinib is an oral, once-daily selective and reversible Janus kinase inhibitor (JAKi)
.
Upadacitinib is an oral, once-daily selective and reversible Janus kinase inhibitor (JAKi)
St.
George's University Hospitals NHS Foundation Dr.
Trust Fund rheumatology consultant Arvind Kaul said: "NICE recommended upadacitinib provides another effective treatment option for patients with psoriatic arthritis activity in England and Wales
Clinical studies show.
, upadacitinib can improve musculoskeletal symptoms, psoriasis, pain and fatigue in people with psoriatic arthritis
.
fund
Original source:
Original source:https:// href="https://" target="_blank" rel="noopener">https:// https:// Leave a comment here